Show Search Form

Search Results

registered interest	true false
date	exactly: or between: and
answering body
answering dept id
answering dept short name
answering dept sort name
hansard heading
house id
legislature	pref label
question text
tabling member printed
uin
answer	is ministerial correction true false date of answer exactly: or between: and answer text answering member printed grouped question UIN question first answered answering member label
tabling member	label

Search

1137952

	registered interest
	date	09/07/2019
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Mortality Rates: Boys
	house id	2
	legislature	25277 pref label House of Lords
	question text	To ask Her Majesty's Government what assessment they have made of the finding of the Office for National Statistics in its mid-year population estimates published in June, that there has been a 14 per cent annual increase in the rate of mortality of boys aged five to nine.
	tabling member printed	Lord Mendelsohn
	uin	HL17051
	answer	answer is ministerial correction date of answer 17/07/2019 answer text <p>The Office for National Statistics data shows that for boys aged five to nine there were 137 deaths in England in the period mid-2017 to mid-2018. This is an increase of 19 deaths compared with the period mid-2016 to mid-2017, when there were 118 deaths. As the number of deaths fluctuate between individual years, a longer period must be looked at for evidence of trends. Public Health England’s review of recent trends in mortality in England, showed that there was an improvement in mortality rates for children aged five to nine between 2011 and 2016. There was also an improvement in early periods, 2001 to 2006, and 2006 to 2011.</p><p>Improving child health outcomes is central to the NHS Long Term Plan and for prioritising services for children and young people. It provides a clear focus on improving the health of children and young people across mental health, learning disabilities, cancer and elsewhere.<strong> </strong></p><p> </p> answering member printed Baroness Blackwood of North Oxford question first answered 17/07/2019 13:33:57 answering member 4019 label Biography information for Baroness Blackwood of North Oxford
	tabling member	4286 label Biography information for Lord Mendelsohn

1137392

	registered interest
	date	08/07/2019
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Lumacaftor/ivacaftor
	house id	2
	legislature	25277 pref label House of Lords
	question text	To ask Her Majesty's Government what plans the Secretary of State for Health and Social Care has to intervene in the ongoing negotiations between Vertex pharmaceuticals, NICE and NHS England on the price of the cystic fibrosis drug Orkambi to ensure that it is made available to patients as soon as possible.
	tabling member printed	Baroness Morgan of Huyton
	uin	HL16999
	answer	answer is ministerial correction date of answer 15/07/2019 answer text <p>NHS England and NHS Improvement is leading the negotiations with Vertex and has made a revised and improved offer to Vertex that would provide immediate funding for Orkambi and Symkevi in advance of a positive assessment by the National Institute for Health and Care Excellence (NICE), in addition to expanded access to Kalydeco which is already funded by the National Health Service for certain patients. No date has been agreed for a further meeting as of yet, however negotiations are ongoing between Vertex, NHS England and NHS Improvement and NICE.</p><p>Cystic fibrosis can have a devastating effect on the lives of those who suffer from it, and those close to them, and the Government wants to see patients access innovative treatments at a cost-effective price for the NHS. The Government fully supports NICE and NHS England in seeking to ensure access for patients to effective and innovative medicines at a price that represents value to the NHS, and it is not for Ministers to intervene in this process. The Department’s approach remains to strongly urge Vertex to accept NHS England and NHS Improvement’s generous offer, but in the absence of a deal, we have asked NHS England and NHS Improvement to continue to explore all options to ensure patients can access treatments as soon as possible.</p> answering member printed Baroness Blackwood of North Oxford grouped question UIN HL16997 HL16998 question first answered 15/07/2019 10:23:54 answering member 4019 label Biography information for Baroness Blackwood of North Oxford
	tabling member	2168 label Biography information for Baroness Morgan of Huyton

1137391

	registered interest
	date	08/07/2019
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Lumacaftor/ivacaftor
	house id	2
	legislature	25277 pref label House of Lords
	question text	To ask Her Majesty's Government what assessment they have made of the impact of the lack of availability of Orkambi on patients with cystic fibrosis; and what plans they have to discuss this issue with (1) patients, and (2) other interested parties.
	tabling member printed	Baroness Morgan of Huyton
	uin	HL16998
	answer	answer is ministerial correction date of answer 15/07/2019 answer text <p>NHS England and NHS Improvement is leading the negotiations with Vertex and has made a revised and improved offer to Vertex that would provide immediate funding for Orkambi and Symkevi in advance of a positive assessment by the National Institute for Health and Care Excellence (NICE), in addition to expanded access to Kalydeco which is already funded by the National Health Service for certain patients. No date has been agreed for a further meeting as of yet, however negotiations are ongoing between Vertex, NHS England and NHS Improvement and NICE.</p><p>Cystic fibrosis can have a devastating effect on the lives of those who suffer from it, and those close to them, and the Government wants to see patients access innovative treatments at a cost-effective price for the NHS. The Government fully supports NICE and NHS England in seeking to ensure access for patients to effective and innovative medicines at a price that represents value to the NHS, and it is not for Ministers to intervene in this process. The Department’s approach remains to strongly urge Vertex to accept NHS England and NHS Improvement’s generous offer, but in the absence of a deal, we have asked NHS England and NHS Improvement to continue to explore all options to ensure patients can access treatments as soon as possible.</p> answering member printed Baroness Blackwood of North Oxford grouped question UIN HL16997 HL16999 question first answered 15/07/2019 10:23:54 answering member 4019 label Biography information for Baroness Blackwood of North Oxford
	tabling member	2168 label Biography information for Baroness Morgan of Huyton

1137390

	registered interest
	date	08/07/2019
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Lumacaftor/ivacaftor
	house id	2
	legislature	25277 pref label House of Lords
	question text	To ask Her Majesty's Government whether a date has been set for Vertex pharmaceuticals, NICE and NHS England to convene a further meeting to discuss how the cystic fibrosis drug Orkambi can be made available to patients.
	tabling member printed	Baroness Morgan of Huyton
	uin	HL16997
	answer	answer is ministerial correction date of answer 15/07/2019 answer text <p>NHS England and NHS Improvement is leading the negotiations with Vertex and has made a revised and improved offer to Vertex that would provide immediate funding for Orkambi and Symkevi in advance of a positive assessment by the National Institute for Health and Care Excellence (NICE), in addition to expanded access to Kalydeco which is already funded by the National Health Service for certain patients. No date has been agreed for a further meeting as of yet, however negotiations are ongoing between Vertex, NHS England and NHS Improvement and NICE.</p><p>Cystic fibrosis can have a devastating effect on the lives of those who suffer from it, and those close to them, and the Government wants to see patients access innovative treatments at a cost-effective price for the NHS. The Government fully supports NICE and NHS England in seeking to ensure access for patients to effective and innovative medicines at a price that represents value to the NHS, and it is not for Ministers to intervene in this process. The Department’s approach remains to strongly urge Vertex to accept NHS England and NHS Improvement’s generous offer, but in the absence of a deal, we have asked NHS England and NHS Improvement to continue to explore all options to ensure patients can access treatments as soon as possible.</p> answering member printed Baroness Blackwood of North Oxford grouped question UIN HL16998 HL16999 question first answered 15/07/2019 10:23:54 answering member 4019 label Biography information for Baroness Blackwood of North Oxford
	tabling member	2168 label Biography information for Baroness Morgan of Huyton

1137097

	registered interest
	date	04/07/2019
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Prescriptions: Fees and Charges
	house id	2
	legislature	25277 pref label House of Lords
	question text	To ask Her Majesty's Government what estimate they have made of the annual cost to NHS England of GP appointments and hospital admissions arising from people with asthma and other long-term health conditions who do not take prescription medications because they cannot afford them.
	tabling member printed	Lord Rennard
	uin	HL16961
	answer	answer is ministerial correction date of answer 15/07/2019 answer text <p>The Department has made no such estimate. Extensive arrangements are already in place to help people access National Health Service prescriptions. These include a broad range of NHS prescription charge exemptions, for which someone with asthma and other long-term health conditions may qualify.</p><p>To support those with greatest need who do not qualify for an exemption, cost of the prescription pre-payment certificates were frozen for another year. A holder of a 12-month certificate can get all the prescriptions they need for just £2 per week.</p> answering member printed Baroness Blackwood of North Oxford question first answered 15/07/2019 10:54:56 answering member 4019 label Biography information for Baroness Blackwood of North Oxford
	tabling member	2484 label Biography information for Lord Rennard

1137096

	registered interest
	date	04/07/2019
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Prescriptions: Fees and Charges
	house id	2
	legislature	25277 pref label House of Lords
	question text	To ask Her Majesty's Government what assessment they have made of any savings made by the NHS in Scotland, Wales and Northern Ireland as a result of not charging for prescriptions.
	tabling member printed	Lord Rennard
	uin	HL16960
	answer	answer is ministerial correction date of answer 15/07/2019 answer text <p>The Department has made no such assessment. All issues relating to healthcare provision are a matter for the devolved administrations.</p> answering member printed Baroness Blackwood of North Oxford question first answered 15/07/2019 10:49:05 answering member 4019 label Biography information for Baroness Blackwood of North Oxford
	tabling member	2484 label Biography information for Lord Rennard

1137095

	registered interest
	date	04/07/2019
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Prescriptions: Fees and Charges
	house id	2
	legislature	25277 pref label House of Lords
	question text	To ask Her Majesty's Government how much it costs NHS England annually to (1) collect payments for free prescriptions, (2) administer the system of medical exemption certificates, and (3) provide prescription prepayment certificates.
	tabling member printed	Lord Rennard
	uin	HL16959
	answer	answer is ministerial correction date of answer 15/07/2019 answer text <p>NHS England and NHS Improvement do not collect any payment for free prescriptions.</p><p>The costs to administer the system of medical exemption certificates is around £1 million. The costs to provide prescription prepayment certificates is around £4.8 million. These figures have been provided by the NHS Business Services Authority and are for the financial period 2018/19.</p><p> </p> answering member printed Baroness Blackwood of North Oxford question first answered 15/07/2019 11:02:36 answering member 4019 label Biography information for Baroness Blackwood of North Oxford
	tabling member	2484 label Biography information for Lord Rennard

1137094

	registered interest
	date	04/07/2019
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Prescriptions: Fees and Charges
	house id	2
	legislature	25277 pref label House of Lords
	question text	To ask Her Majesty's Government what estimate they have made, if any, of the annual cost to the NHS of providing free prescriptions to those with (1) asthma, and (2) long-term health conditions.
	tabling member printed	Lord Rennard
	uin	HL16958
	answer	answer is ministerial correction date of answer 15/07/2019 answer text <p>The Department has made no such estimate. Extensive arrangements are already in place to help people access National Health Service prescriptions. These include a broad range of NHS prescription charge exemptions.</p><p>To support those with greatest need who do not qualify for an exemption, cost of the prescription pre-payment certificates were frozen for another year. A holder of a 12-month certificate can get all the prescriptions they need for just £2 per week.</p><p> </p> answering member printed Baroness Blackwood of North Oxford question first answered 15/07/2019 10:26:36 answering member 4019 label Biography information for Baroness Blackwood of North Oxford
	tabling member	2484 label Biography information for Lord Rennard

1137093

	registered interest
	date	04/07/2019
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Prescriptions: Fees and Charges
	house id	2
	legislature	25277 pref label House of Lords
	question text	To ask Her Majesty's Government what representations they have received about prescription charges for people with lifetime health conditions in the last two years; whether they record the health conditions each such representation related to; and how many people in England they estimate are subject to prescription charges for such conditions.
	tabling member printed	Lord Rennard
	uin	HL16957
	answer	answer is ministerial correction date of answer 15/07/2019 answer text <p>We have received a number of representations from Parliamentarians, stakeholders, individuals and other interested parties on prescription exemptions for people with long term health conditions. Whether any specific health condition was mentioned in each such representation is not recorded centrally and to obtain this information would incur disproportionate cost. Furthermore, the Department has made no estimate of the number of people in England that are subject to prescription exemptions for such conditions. However, around 89% of National Health Service prescription items are dispensed in the community free of charge.</p><p> </p> answering member printed Baroness Blackwood of North Oxford question first answered 15/07/2019 10:26:15 answering member 4019 label Biography information for Baroness Blackwood of North Oxford
	tabling member	2484 label Biography information for Lord Rennard

1137092

	registered interest
	date	04/07/2019
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Prescriptions: Fees and Charges
	house id	2
	legislature	25277 pref label House of Lords
	question text	To ask Her Majesty's Government, further to the answer by Baroness Blackwood of North Oxford on 3 July (HL Deb, col 1435), what assessment they have made of the finding of the House of Commons Health Committee in its report NHS Charges (HC815–1), published on 18 July 2006, that the list of exemptions for prescription charges was “inconsistent and anomalous”; and what plans they have, in any future meetings with Asthma UK, to discuss the current list of exemptions for prescription charges in regard to those who have asthma.
	tabling member printed	Lord Rennard
	uin	HL16956
	answer	answer is ministerial correction date of answer 15/07/2019 answer text <p>The Department has made no formal assessment of the finding of the House of Commons Health Committee in its report NHS Charges (HC815–1), published on 18 July 2006, that the list of exemptions for prescription charges was “inconsistent and anomalous”. The Department has no current plans to review the existing National Health Service prescription charging exemption arrangements.</p> answering member printed Baroness Blackwood of North Oxford question first answered 15/07/2019 11:04:01 answering member 4019 label Biography information for Baroness Blackwood of North Oxford
	tabling member	2484 label Biography information for Lord Rennard